Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients

• Published in: Mayo Clinic proceedings Vol. 90; no. 6; pp. 756 - 764
• Main Authors: Tadmor, Tamar, MD, Bari, Alessia, MD, Marcheselli, Luigi, MS, Sacchi, Stefano, MD, Aviv, Ariel, MD, Baldini, Luca, MD, Gobbi, Paolo G., MD, Pozzi, Samantha, MD, Ferri, Paola, MS, Cox, Maria Christina, MD, Cascavilla, Nicola, MD, Iannitto, Emilio, MD, Federico, Massimo, MD, Polliack, Aaron, MD
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.06.2015; Elsevier, Inc; Elsevier Limited
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Analysis; Cohort Studies; Female; Hodgkin Disease - blood; Hodgkin Disease - diagnosis; Hodgkin Disease - mortality; Humans; Internal Medicine; Italy; Kaplan-Meier Estimate; Leukocyte Count; Lymphocytes; Male; Middle Aged; Monocytes; Non-Hodgkin's lymphomas; Patient outcomes; Predictive Value of Tests; Prognosis; Survival Rate; Young Adult; Italy; Taiwan; TAM; dAUC; NS; PET-CT; tumor-associated macrophage; HR; non-Hodgkin lymphoma; absolute lymphocyte count; IPS; positron emission tomography–computed tomography; NHL; AMC; lymphocyte- monocyte ratio; overall survival; WBC; PFS; receiver operating characteristic; white blood cell; delta (difference) of AUC between ROC curve analysis at 5-year follow-up with IPS and IPS + AMC or LMR; OS; cHL; progression-free survival; ROC; classical Hodgkin lymphoma; LMR; nodular sclerosis; international prognostic score; ALC; hazard ratio; absolute monocyte count
• ISSN: 0025-6196; 1942-5546
• DOI: 10.1016/j.mayocp.2015.03.025

Abstract Objective To verify whether absolute monocyte count (AMC) and lymphocyte- monocyte ratio (LMR) at diagnosis are valid prognostic parameters in classical Hodgkin lymphoma (cHL). Patients and Methods Data were collected from 1450 patients with cHL treated in Israel and Italy from January 1, 1988, through December 31, 2007. Results The median age of the patients was 33 years (range, 17-72 years), and 70% (1017) of the patients had nodular sclerosis (NS); the median follow-up duration was 87 months. The best cutoff value for AMC was 750 cells/mm3 , and the best ratio for LMR was 2.1. The adverse prognostic impact of an AMC of more than 750 cells/mm3 was confirmed for the entire cohort, and its clinical significance was particularly evident in patients with NS histology. The progression-free survival (PFS) at 10 years for an AMC of more than 750 cells/mm3 was 65% (56%-72%), and the PFS at 10 years for an AMC of 750 cells/mm3 or less was 81% (76%-84%; P <.001). The overall survival (OS) at 10 years for an AMC of more than 750 cells/mm3 was 78% (70%-85%), and the OS at 10 years for an AMC of 750 cells/mm3 or less was 88% (84%-90%; P =.01). In multivariate analysis, both AMC and LMR maintained prognostic significance for PFS (hazard ratio [HR], 1.54, P =.006, and HR, 1.50, P =.006) after adjusting for the international prognostic score, whereas the impact on OS was confirmed (HR, 1.56; P =.04) only in patients with NS and an AMC of more than 750 cells/mm3. Conclusion This study confirms that AMC has prognostic value in cHL that is particularly significant in patients with NS subtype histology. This finding links the known impact of macrophages and monocytes in Hodgkin lymphoma with routine clinical practice.